产前物质使用筛查普遍推荐下仍存异质性:2016-2018年妊娠风险评估监测系统发现
该研究分析2016-2018年妊娠风险评估监测系统(PRAMS)中103,608名近期活产妇女数据,描述产前物质使用筛查的患病率及政策与个体因素关联。2018年约95%报告被询问吸烟或饮酒,仅80%被询问药物使用;各州差异存在,将产前药物使用定为虐待/忽视的州筛查率较低,强制检测的州较高。
要点
- 2018年约95%孕妇报告被询问吸烟或饮酒,仅80%被询问药物使用。
- 将产前药物使用定为虐待/忽视的州筛查率较低,强制检测的州较高。
- 年轻、低教育、未婚、黑人、非西班牙裔、公共保险等人群筛查几率更高。
核心结论
- 尽管推荐普遍产前物质使用筛查,实际被询问物质使用的人群存在差异,可能受州政策和选择性筛查方法影响。
研究设计与样本
- 基于人群的调查研究,分析2016-2018年PRAMS中103,608名近期活产妇女数据,应用抽样权重。
- 使用卡方检验比较州级政策下筛查率差异,逻辑回归分析个体因素与筛查接受关联,控制年份和州固定效应,多重插补处理缺失。
主要发现
- 2018年约95%个体报告在产前检查时被询问吸烟或饮酒,仅80%被询问药物使用。
- 2016至2018年总体被询问物质使用的百分比增加,但各州存在变异。
- 所有物质中,将产前药物使用定为虐待/忽视的州筛查率较低,强制提供者检测的州筛查率较高。
- 与筛查几率增加相关的个体特征包括更年轻、教育程度更低、未婚、黑人(对比白人)、非西班牙裔、公共保险(对比私人保险)、接受充分产前保健、孕前吸烟史。
关键数值与推荐
- 美国妇产科医师学会推荐将烟草、酒精和药物使用筛查作为常规产前保健的一部分。
临床怎么用
- 临床应实施普遍物质使用筛查,避免选择性筛查,并关注州政策及提供者偏见对筛查实施的影响。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The American College of Obstetricians and Gynecologists recommends universal screening for tobacco, alcohol, and drug use as a part of routine prenatal care. However, little is known about the prevalence of prenatal substance use screening or factors that may contribute to differential rates of screening during prenatal care. OBJECTIVE: This study aimed to describe the prevalence of prenatal substance use screening by substance, year, state, and state-level prenatal substance use policies and to examine individual-level factors associated with receipt of screening. STUDY DESIGN: We analyzed 2016 to 2018 data from 103,608 women participating in the Pregnancy Risk Assessment Monitoring System, a population-based survey among women with recent live births. The Pregnancy Risk Assessment Monitoring System survey sampling weights were applied to all analyses. We described the percentage of individuals asked by a healthcare worker about substance use during a prenatal care appointment by substance, year, and state. Using chi-squared tests, we examined differences in the prevalence of screening by state-level prenatal substance use policies, including policies regarding classification of prenatal substance use as child abuse or neglect, mandatory testing or reporting of prenatal substance use, and targeted treatment funding and access for pregnant individuals with substance use disorders. Finally, we estimated the association between individual-level characteristics and receipt of prenatal substance use screening using logistic regression, controlling for year and state fixed effects and accounting for missingness using multiple imputation. RESULTS: In 2018, approximately 95% individuals reported being asked about cigarette or alcohol use during a prenatal care appointment, whereas only 80% reported being asked about drug use. The percentage of individuals who were asked about substance use during a prenatal care appointment increased overall between 2016 and 2018, with variability across states. For all substances, states with laws designating prenatal drug use as child abuse or neglect had lower prevalence of screening, whereas states with laws mandating providers to test for substance use in pregnancy had higher prevalence of screening. Several individual-level characteristics were associated with increased odds of reported prenatal substance use screening for one or more substances, including being younger, less educated, unmarried, Black (vs White), non-Hispanic, or publicly insured (vs privately insured), receiving adequate prenatal care, and having a history of prepregnancy cigarette use. CONCLUSION: Our study finds that despite recommendations for universal prenatal substance use screening, there are differences in who is actually asked about substance use during prenatal care appointments. This may be influenced by state-level prenatal substance use policies and selective screening approaches in which certain individuals are more likely to be asked about substance use during their prenatal care appointment. A better understanding of the repercussions of selective screening approaches on outcomes and the roles that policies, systems, and provider biases play in perpetuating these approaches is needed to advance guideline implementation efforts in prenatal care settings.
引用
- Patel E, Bandara S, Saloner B, et al. Heterogeneity in prenatal substance use screening despite universal screening recommendations: findings from the Pregnancy Risk Assessment Monitoring System, 2016-2018. Am J Obstet Gynecol MFM. 2021. PMID: 34116233. doi:10.1016/j.ajogmf.2021.100419
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。